Targeting Activated KIT Signaling for Melanoma Therapy

University of California at San Francisco, San Francisco, CA.
Journal of Clinical Oncology (Impact Factor: 18.43). 08/2013; 31(26). DOI: 10.1200/JCO.2013.50.3227
Source: PubMed
Download full-text


Available from: Rosaura Esteve-Puig, Dec 23, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Most melanomas present as primary tumors on the skin surface in adults; however, melanomas also arise in the eye and on the mucosal surfaces or present as apparently metastatic disease without any known history of a cutaneous primary. Melanoma is also being diagnosed during childhood more frequently than ever. Surgeons need to be aware of and understand these unusual presentations of melanoma to optimally manage their patients.
    Surgical Clinics of North America 10/2014; 94(5). DOI:10.1016/j.suc.2014.07.010 · 1.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Before 2011, patients with advanced or metastatic melanoma had a particularly poor long-term prognosis. Since traditional treatments failed to confer a survival benefit, patients were preferentially entered into clinical trials of investigational agents. A greater understanding of the epidemiology and biology of disease has underpinned the development of newer therapies, including six agents that have been approved in the EU, US and/or Japan: a cytotoxic T-lymphocyte antigen-4 inhibitor (ipilimumab), two programmed cell death-1 receptor inhibitors (nivolumab and pembrolizumab), two BRAF inhibitors (vemurafenib and dabrafenib) and a MEK inhibitor (trametinib). The availability of these treatments has greatly improved the outlook for patients with advanced melanoma; however, a major consideration for physicians is now to determine how best to integrate these agents into clinical practice. Therapeutic decisions are complicated by the need to consider patient and disease characteristics, and individual treatment goals, alongside the different efficacy and safety profiles of agents with varying mechanisms of action. Long-term survival, an outcome largely out of reach with traditional systemic therapies, is now a realistic goal, creating the additional need to re-establish how clinical benefit is evaluated. In this review we summarise the current treatment landscape in advanced melanoma and discuss the promise of agents still in development. We also speculate on the future of melanoma treatment and discuss how combination and sequencing approaches may be used to optimise patient care in the future. Copyright © 2015. Published by Elsevier Ltd.
    Cancer Treatment Reviews 06/2015; 41(8). DOI:10.1016/j.ctrv.2015.05.012 · 7.59 Impact Factor